On January 30, CSPC Pharmaceutical and AstraZeneca have entered into a strategic collaboration and license agreement with a potential total value of $18.5 billion to develop innovative long-acting peptide medicines. The partnership will leverage CSPC's proprietary sustained-release delivery technology and AI-driven peptide discovery platforms.

Among the transaction's projects, the product involved in the collaboration and licensing between CSPC Megalith Biopharmaceutical and AstraZeneca primarily relates to an innovative peptide molecule along with related technologies and products, currently in the preclinical research stage. It aims to provide a longer-lasting treatment solution for individuals with obesity and weight-related concerns. Furthermore, there exists the possibility for CSPC Megalith Biopharmaceutical and AstraZeneca to engage in strategic collaboration on other related projects in the fields of innovative peptide molecule discovery and long-acting delivery product development.

Ranked 217th on the Fortune Global 500 list, MSD has been dedicated to the biopharmaceutical field for over 130 years, consistently committed to providing innovative health solutions through medicines, vaccines, biologic therapies, and animal health products.

SIM0709 is a novel long-acting humanized bispecific antibody developed from Simcere's proprietary multi-specific antibody platform. It simultaneously targets Tumor Necrosis Factor-like Ligand 1A (TL1A) and Interleukin-23 (IL-23), blocking two core pathways that drive the onset and progression of Inflammatory Bowel Disease (IBD). This positions SIM0709 with first-in-class potential in the treatment of IBD.

gMG is a rare, debilitating, chronic autoimmune neuromuscular disorder that can lead to muscle function loss and severe debilitation.

In mid-2025, EY-Parthenon predicted that the global medical device market would grow at an annual rate of approximately 6%, indicating steady overall market expansion. The medical device industry is undergoing a shift in growth drivers, with multinational corporations (MNCs) intensively divesting or selling off underperforming or slower-growth businesses to focus on higher-growth segments. While certain areas of the industry are losing momentum, which emerging segments are rising to become the new engines of growth?

This drug candidate is intended for the prophylactic protection against food allergens and is currently in Phase IIb clinical development. Pursuant to the agreement, GSK will obtain the global rights (excluding Chinese Mainland, Hong Kong, Macau, and Taiwan) to develop and commercialize ozureprubart. Concurrently, GSK will assume the responsibility for future success-based milestone and royalty payments owed to RAPT's partner, Shanghai Jeyou Pharmaceutical Co., Ltd.

IgE is a clinically validated target and is the only approved systemic therapy shown to protect patients from a harmful allergic and inflammatory immune response. Around 94% of severe food allergies are caused by IgE-mediated reactions.

C-CAR031 is an autologous, Glypican-3 (GPC3)-targeting chimeric antigen receptor T-cell (CAR-T) therapy. Based on AstraZeneca's novel GPC3-targeting CAR-T candidate (AZD5851), it is designed using AstraZeneca's dominant negative transforming growth factor-beta receptor II (dnTGFβRII) armoring platform and is manufactured by AbelZeta in China. It is currently being investigated for the treatment of hepatocellular carcinoma (HCC) and other solid tumors.

At JPM 2026, 24 Chinese innovative biopharmaceutical companies presented in the main conference and Asia-Pacific sessions, while an even greater number completed significant licensing deals with multinational corporations during the event. In key focus areas at JPM 2026, such as antibody-drug conjugates (ADCs), metabolic diseases, and cell and gene therapies, Chinese innovative drugs have become an indispensable source of value.

Given the complexity of the CNS and the challenges in drug development, there remains a substantial unmet clinical need for many CNS diseases. With continuous advancements in sophisticated research instruments, fundamental research in the CNS field has reached a tipping point.

The asset has been developed internally by PepLib to date. Through this transaction, Novartis, anexperienced global leader in RLTs, will advance the program to its next stage of development.

Reportedly, traditional ADC drugs still have several limitations. First, for an ADC to exert its therapeutic effect, the antibody component must be internalized by cells, which restricts the selection of suitable antibodies. Furthermore, the release of the ADC's payload involves multiple steps, such as tumor cell endocytosis and lysosomal degradation, each of which may lead to treatment failure or drug resistance.

On December 31, 2025, Zelgen Biopharmaceuticals announced that it has entered into a strategic collaboration and option agreement with an affiliate of AbbVie. for the global development and commercialization of ZG006 (Alveltamig). The candidate, ZG006, is a novel trispecific T-cell engager targeting DLL3, currently in late-stage clinical development for the treatment of small cell lung cancer and other DLL3-expressing malignant tumors.

Recently, disease control and prevention centers across China have rolled out subsidized vaccination initiatives for herpes zoster. Two approved herpes zoster vaccines in China have undergone significant price reductions: the second dose of GSK's imported recombinant herpes zoster vaccine (brand name: Shingrix®) is now offered free of charge, while the domestic herpes zoster live attenuated vaccine produced by BCHT (brand name: Gan Wei) is available at a discount of 30% to 80%.

Looking back to April 17, 2025, Sanofi had previously secured global exclusive rights to two bispecific antibodies from Helixon—HXN-1002 (targeting α4β7/TL1A) and HXN-1003 (targeting TL1A/IL-23)—with an upfront payment of $125 million and a total potential deal value of up to $1.845 billion.

On December 22, AstraZeneca's Benralizumab Injection (brand name: Fasenra®, generic name: Benralizumab Injection) received approval from the China National Medical Products Administration (NMPA) for a new indication, for the treatment of adult eosinophilic granulomatosis with polyangiitis (EGPA).

ZG006 is a novel trispecific T-cell engager targeting two distinct DLL3 epitopes and CD3. It represents the world's first DLL3-targeting trispecific antibody (CD3/DLL3/DLL3) with best-in-class potential. Currently, it is in late-stage clinical development for the treatment of small cell lung cancer (Phase III) and other DLL3-expressing malignancies.

This trend not only marks the transition of bispecific antibody technology from a niche field to a mainstream focus but also signals its potential to replace traditional monoclonal antibodies and antibody-drug conjugates as the cornerstone of next-generation biopharmaceutical development.

On December 12, Eli Lilly released updated results from the Phase 3 EMBER-3 clinical trial of imlunestrant, an oral estrogen receptor antagonist. The study enrolled patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–) advanced or metastatic breast cancer (MBC) who had previously received treatment with an aromatase inhibitor (AI) with or without a CDK4/6 inhibitor and experienced disease progression. Compared with endocrine therapy, imlunestrant monotherapy showed a clinically meaningful 38% reduction in the risk of disease progression or death in patients harboring ESR1 mutations.